aav-haadc-2
Gene therapyexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2004 (NCT00229736)
Timeline
Indications
Mechanism of action
- DOPA decarboxylaseSupplementation
DDC supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav2-haadc
- aav-haadc-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07267065 | Phase 1 | Feb 1, 2026 | Ohio State University |
| NCT02926066 | Phase 2 | Sep 1, 2016 | National Taiwan University |
| NCT02852213 | Phase 1 | Jul 1, 2016 | National Institutes of Health (NIH), University of California, San Francisco |
| NCT02418598 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Gene Therapy Research Institution,Co.,Ltd., Jichi Medical University, Takara Bio Inc. |
| NCT00229736 | Phase 1 | Nov 1, 2004 | Genzyme |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gene Therapy Research Institution,Co.,Ltd. | For profit | 1 | 0 | 1 | 2015 |
| Genzyme | For profit | 1 | 1 | 1 | 2004 |
| Jichi Medical University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2016 |
| National Taiwan University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Takara Bio Inc. | For profit | 1 | 0 | 1 | 2015 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2016 |
8 organizations
Page 1 / 1